Howard Berman is the CEO and co-founder of Coya Therapeutics, a Houston biotech company focused on Alzheimer's and other neurodegenerative diseases.
But when Berman's father was diagnosed with dementia, he was moved to action.
"I was interested in what I could do for my dad," Berman tells the Houston Innovators podcast.
So Berman teamed up with Stanley Appel, a neurologist at Houston Methodist Research Institute, to work on Alzheimer's and other neurodegenerative diseases.
Appel was able to stop the progression of ALS, also known as Lou Gehrig's disease, with one of Berman's treatments.
Now, Berman says, he's working on treatments for other neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, or ALS, which is also known as Lou Gehrig's disease.
Coya's lead treatment is a drug-eluting balloon that's currently in a clinical trial for Alzheimer's and other neurodegenerative diseases.
But it could also be used to treat other neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, or ALS, which is also known as Lou Gehrig's disease, the Houston Chronicle reports.
Berman's father died of
A customized collection of grant news from foundations and the federal government from around the Web.
Philanthropy imparts a multitude of ways for small business owners to do social good – both for the community and for themselves.